Recon: Lilly to acquire DICE in $2.4B deal; FDA places hold on Gilead BCMA CAR-T trial
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyReconJoanne S. EglovitchBiologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy